1. Woo SC, Lip GY, Lip PL. Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. Eye (Lond) . 2016;30:1031-1038. doi: 10.1038/eye.2016.111
2. Cugati S, Wang JJ, Rochtchina E, et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol . 2006;124:726. doi: 10.1001/archopht.124.5.726
3. O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol . 2008;126:692-699. doi: 10.1001/archopht.126.5.692
4. Hayreh SS, Zimmerman B, McCarthy MJ, et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol . 2001;131:61-77. doi: 10.1016/s0002-9394(00)00709-1
5. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost . 2005;93:1021-1026. doi: 10.1160/TH04-11-0768
6. Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost . 2008;99:925-929. doi: 10.1160/TH07-11-0658
7. Yin X, Li J, Zhang B, et al. Association of glaucoma with risk of retinal vein occlusion: a meta-analysis. Acta Ophthalmol . 2019;97:652-659. doi: 10.1111/aos.14141
8. Rehak M, Krcova V, Slavik L, et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol . 2010;45:171-175. doi: 10.3129/i09-273
9. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrent and demographic characteristics. Am J Ophthalmol . 1994;117:429-441. doi: 10.1016/s0002-9394(14)70001-7
10. Hayreh SS, Klugman MR, Beri M, et al. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol . 1990;228:201-217. doi: 10.1007/BF00920022
11. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology . 2011;118:119-133. doi: 10.1016/j.ophtha.2010.04.019
12. Bakri SJ, Berrocal A, Capone A, et al. Retina health series: central retinal vein occlusion. American Society of Retina Specialists . January 2020. Accessed April 16, 2021. www.asrs.org/content/documents/fact-sheet-21-central-retinal-vein-occlusion-2020_1_asrs.pdf
13. Columbia University Department of Ophthalmology. Proliferative diabetic retinopathy (PDR). Accessed July 2, 2021. www.columbiaeye.org/education/digital-reference-of-ophthalmology/vitreous-retina/retinal-vascular-diseases/proliferative-diabetic-retinopathy-pdr
14. Mehta S. Diabetic retinopathy. Merck Manual Professional Version. Updated June 2021. Accessed July 11, 2021. www.merckmanuals.com/professional/eye-disorders/retinal-disorders/diabetic-retinopathy
15. Gertz MA. Acute hyperviscosity: syndromes and management. Blood 2018;132:1379-1385. doi: 10.1182/blood-2018-06-846816
16. Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome—a systematic review. Med Sci Monit. 2012;18: RA138-RA144. doi: 10.12659/msm.883260
17. Moisseiev E, Sagiv O, Lazar M. Intense exercise causing central retinal vein occlusion in a young patient: case report and review of the literature. Case Rep Ophthalmol . 2014;5:116-120. doi: 10.1159/000360904.
18. Weiss KD, Kuriyan AE, Flynn HW Jr. Central retinal vein occlusion after prolonged vomiting and repeated valsalva maneuvers associated with gastroenteritis and dehydration. Ophthalmic Surg Lasers Imaging Retina . 2014;45:e23-e25. doi: 10.3928/23258160-20140331-03
19. Jacobs DJ, Flynn HW, Pathengay A, et al. Central retinal vein occlusion after intense exercise: response to intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging . 2011;42:e59-e62. doi: 10.3928/15428877-20110623-02
20. Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology . 2007;114:507-524. doi: 10.1016/j.ophtha. 2006.11.011
21. Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmol . 2008;86:245-252. doi: 10.1111/j.1755-3768.2007.01144.x
22. Braithwaite T, Nanji AA, Greenberg PB. Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev . 2010;10:CD007325. doi: 10.1002/14651858.CD007325.pub2
23. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology . 2010;117:1124-1133. doi: 10.1016/j.ophtha.2010.02.022
24. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology . 2011;118:2041-2049. doi: 10.1016/j.ophtha.2011. 02.038
25. Prasad AG, Schadlu R, Apte RS. Intravitreal pharmacotherapy: applications in retinal disease. Compr Ophthalmol Update. 2007; 8:259-269.
26. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol . 2013;155:429-437. doi: 10.1016/j.ajo.2012.09.026
27. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol . 2009;127:1101-1114. doi: 10.1001/archophthalmol.2009.234
28. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology . 1995;102:1434-1444.